Halozyme Therapeutics (HALO) investor relations material

Strategic acquisitions and technology expansion

• Acquired Elektrofi and Surf Bio, adding two hyperconcentration technologies with IP protection into the mid-2040s, broadening collaboration opportunities and extending revenue visibility.

• Now offers three royalty-bearing subcutaneous delivery platforms: ENHANZE, Hypercon, and Surf Bio, positioning as a one-stop shop for biopharma partners.

• Acquired Surf Bio for $300M upfront and up to $100M in milestones, and Elektrofi for $750M upfront and up to $150M in milestones, both funded from existing cash with minimal leverage impact.

• Hypercon and Surf Bio enable ultra-high concentration SC delivery, supporting smaller injection volumes, at-home administration, and lifecycle optimization for monoclonal antibodies, peptides, and small molecules.

• Both new technologies are expected to drive additional launches and revenue streams into the 2030s.

Financial performance and guidance updates

• 2025 total revenue projected at $1,385–$1,400 million, a 36–38% increase over 2024, with royalty revenue of $865–$870 million, up 51–52%.

• 2026 guidance raised: total revenue expected at $1,710–$1,810 million (23–30% growth), royalty revenue at $1,130–$1,170 million (30–35% growth), adjusted EBITDA $1,125–$1,205 million, and non-GAAP EPS projected at $7.75–$8.25.

• 2028 total revenue projected to exceed $2 billion, with royalty revenue of $1.46–$1.51 billion and non-GAAP EPS of $10.50–$11.10.

• 2024–2028 CAGR projected at 19–21% for total revenue and 26–28% for royalties.

• Gross margin expected to exceed 80%, free cash flow over 70% of EBITDA, and operating margin above 60% for 2026–2028.

Growth drivers and future outlook

• ENHANZE remains a robust contributor, with 10 approved products and 13 in development by end of 2026; new licensing agreements expected to extend royalty durability into the 2040s.

• Hypercon projected to deliver up to $1 billion in royalty revenues by the mid-2030s, with additional launches anticipated.

• 1–3 new licensing agreements projected annually, expanding into nucleic acids and ADCs.

• M&A remains a key strategy, targeting further technology and revenue growth opportunities.

• FDA regulatory changes and accumulated safety data are enabling more streamlined clinical development, potentially shortening timelines for new product approvals.